Bone mineral density in long-term depot medroxyprogesterone acetate acceptors

Area of Science:

• Endocrinology
• Bone Metabolism
• Reproductive Health

Background:

• Depot medroxyprogesterone acetate (DMPA) is a widely used hormonal contraceptive.
• Concerns exist regarding potential adverse effects of DMPA on bone mineral density (BMD) due to its impact on serum estradiol levels.

Purpose of the Study:

• To compare bone mineral density (BMD) in long-term users of DMPA with users of intrauterine devices (IUDs).
• To investigate the relationship between serum estradiol levels and BMD in DMPA users.

Main Methods:

• A comparative study involving 50 long-term DMPA users (≥36 months) and 50 IUD users.
• Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DEXA) at the distal and ultradistal forearm.
• Serum estradiol levels were quantified using microparticle enzyme immunoassay.

Main Results:

• No statistically significant difference in mean BMD of the distal forearm was observed between DMPA and IUD users.
• Similarly, no significant difference in mean BMD of the ultradistal forearm was found between the two groups.
• Serum estradiol levels were significantly lower in DMPA users compared to IUD users.

Conclusions:

• Long-term DMPA use does not appear to have an adverse effect on bone density.
• Reduced serum estradiol levels associated with DMPA do not translate to decreased bone mineral density in the forearm.
• DMPA remains a safe contraceptive option regarding bone health in the studied population.